Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 10, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It strictly reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume per Executive | Exchange |
|---|---|---|---|---|
| March 9, 2017 | Ordinary Shares (25p each) | £16.732 | 14 Shares | London Stock Exchange (XLON) |
Note: The volume of 14 shares per executive consists of 7 partnership shares and 7 matching shares acquired under the Company's ShareReward Plan.
Material Changes
The filing does not contain comparative financial data or material changes to the company's business operations. It reports routine compliance notifications for share acquisitions by senior management.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of specific transactions.
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of Ordinary Shares under the ShareReward Plan, not open market purchases or sales.
- Participants: The filing covers 11 senior executives, including CEO Sir Andrew Witty, CEO Designate Ms E Walmsley, and CFO Mr S Dingemans.
- Volume: The share volume per individual (14 shares) is nominal and reflects the structure of the reward plan rather than significant capital deployment.
- Price: The transaction price was uniform at £16.732 per share for all participants on the transaction date.